Clinical Trial

Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual SymposiumZevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

New clinical efficacy and safety data for arimoclomol as a possible treatment for Niemann-Pick disease type C, including from long-term…

5 months ago
Capricor Therapeutics to Present at Upcoming Investor and Scientific ConferencesCapricor Therapeutics to Present at Upcoming Investor and Scientific Conferences

Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences

SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based…

5 months ago
Safety Shot Announces Notice of Allowance for New Patent to Secure IP and Enforce Clinically Backed ClaimsSafety Shot Announces Notice of Allowance for New Patent to Secure IP and Enforce Clinically Backed Claims

Safety Shot Announces Notice of Allowance for New Patent to Secure IP and Enforce Clinically Backed Claims

New Patent is Added to the Company’s Portfolio of Formulations that Rapidly Reduce Blood Alcohol Content JUPITER, Fla., Sept. 06,…

5 months ago
Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s DiseaseVentyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease

Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease

Results from this trial are expected in 2025SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX)…

5 months ago
Gladstone Institutes Launches Capital Campaign to Accelerate a Biomedical RevolutionGladstone Institutes Launches Capital Campaign to Accelerate a Biomedical Revolution

Gladstone Institutes Launches Capital Campaign to Accelerate a Biomedical Revolution

The $350 million Gladstone NOW campaign will raise funds to expand Gladstone's footprint, hire hundreds of additional scientists, and seize…

5 months ago
Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024

SAN DIEGO, CA / ACCESSWIRE / September 5, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata" or the "Company"), a…

5 months ago
New Treatments in Development Offer Hope for Thousands of Canadian Pulmonary Fibrosis (PF) Patients After Nearly a Decade of AnticipationNew Treatments in Development Offer Hope for Thousands of Canadian Pulmonary Fibrosis (PF) Patients After Nearly a Decade of Anticipation

New Treatments in Development Offer Hope for Thousands of Canadian Pulmonary Fibrosis (PF) Patients After Nearly a Decade of Anticipation

With ongoing investigation into PF and other diseases that inflame and permanently scar lung tissue, researchers are hoping to stop…

5 months ago
Ovation.io and PD Theranostics (PDTx) Complete Merger Creating a Multiomic Data Company Which Owns a Unique Population-Scale Biobank of Disease-Specific BiospecimensOvation.io and PD Theranostics (PDTx) Complete Merger Creating a Multiomic Data Company Which Owns a Unique Population-Scale Biobank of Disease-Specific Biospecimens

Ovation.io and PD Theranostics (PDTx) Complete Merger Creating a Multiomic Data Company Which Owns a Unique Population-Scale Biobank of Disease-Specific Biospecimens

Ovation owns a unique population-scale biobank of consented and linkable disease-specific biospecimens, which includes more than 1.6 million samples from…

5 months ago
Lucius Partners Portfolio Company, PD Theranostics, Completes its Merger with Ovation.io Creating a Multiomic Data Company Which Owns a Unique Population-Scale Biobank of Disease-Specific BiospecimensLucius Partners Portfolio Company, PD Theranostics, Completes its Merger with Ovation.io Creating a Multiomic Data Company Which Owns a Unique Population-Scale Biobank of Disease-Specific Biospecimens

Lucius Partners Portfolio Company, PD Theranostics, Completes its Merger with Ovation.io Creating a Multiomic Data Company Which Owns a Unique Population-Scale Biobank of Disease-Specific Biospecimens

Ovation owns a unique population-scale biobank of consented and linkable disease-specific biospecimens, which includes more than 1.6 million samples from over…

5 months ago
SOPHiA GENETICS Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024SOPHiA GENETICS Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024

SOPHiA GENETICS Announces Validation of Novel Clinical Trial Assay Together with Precision for Medicine at World Clinical Biomarkers & CDx 2024

The companies share how their collaboration enables clinical trial enrollment for a novel cancer therapy for oncogene amplified cancers in…

5 months ago